VYNE Stock Analysis: Buy, Sell, or Hold?
VYNE - VYNE Therapeutics Inc. Common Stock
$28.56
28.05 (5511.00%)
▲
5d:
+3435.53%
30d:
+4282.38%
90d:
+4327.22%
WAIT
LOW Confidence
Analysis Updated: Jul 27, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Get Alerted When VYNE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: VYNE is 267.1% above its trading range ($7.78). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: VYNE is 267.1% above its trading range ($7.78). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: VYNE is currently trading at $28.56, which is considered extended relative to its 30-day fair value range of $-3.82 to $7.78.
Technical Outlook: Technically, VYNE is in a strong downtrend. The price is approaching resistance at $28.56. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5511.0% recently.
Market Sentiment: VYNE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $2.00. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VYNE is in a strong downtrend. The price is approaching resistance at $28.56. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5511.0% recently.
Market Sentiment: VYNE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $2.00. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$-3.82 -
$7.78
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
47.4%
All Signals
- BEARISH: Price significantly overextended (+267.1% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5511.0%)
- BEARISH: Trading 93.0% above Wall St target ($2.00)
- WARNING: Recommendation downgraded due to 267.1% overvaluation
Trading Range Analysis
30-Day Trading Range
$-3.82 -
$7.78
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.47
Resistance Level
$28.56
Current Trend
Strong Downtrend
Technical data as of
Jul 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.35
Wall Street Target
$2.00
(-93.0%)
Revenue Growth (YoY)
-57.4%
Share & Embed Analysis
Last updated: August 03, 2026 10:20 PM ET
Data refreshes hourly during market hours. Next update: 11:20 PM
Data refreshes hourly during market hours. Next update: 11:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VYNE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$57 | 57 HOLD |
